Please enable Javascript
T-cell acute lymphoblastic leukemia
FDA Grants Fast Track, Rare Pediatric Disease Designations to WU-CART-007 for T-ALL, ALL
Leah Sherwood
Transplantation & Cellular Therapy
|
November 16, 2022
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007.
Read More
First Dose of Off-the-Shelf CAR T Given to Patients with R/R T-ALL/LBL
Leah Lawrence
T-Cell Lymphoma
|
April 4, 2022
WU-CART-007 is being tested as part of a phase 1/2 trial to evaluate if off-the-shelf therapy is safe and feasible.
Read More
Advertisement
Advertisement
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer